REGULATORY

• Label Revision Ordered for Opdivo, Yervoy to Add Meningitis Risks
  June 14, 2023

• MHLW to Set Up Team Dedicated to Executing Healthcare DX Timeline
  June 13, 2023

• 3 Japan Manufacturers of Plasma-Derived Products Call for Changes in Export Rules: PAFSC Committee
  June 13, 2023

• Panelist Suggested Macroeconomic Indexing for Social Security Spending: CEFP Minutes
  June 13, 2023

• MHLW Publishes Final Report by Expert Panel on Comprehensive Pharma Policy
  June 13, 2023

• MHLW Panel OKs 170 More Health Damage Claims for COVID Vaccines
  June 13, 2023

• Japan Diet Enacts Genomic Medicine Promotion Bill
  June 12, 2023

• MHLW Calls for Switch from Noritren after Carcinogen Detection
  June 12, 2023

• Honebuto Social Security Debate Culminates with LDP Push for Nixing Budget Cap
  June 9, 2023

• Sumitomo to Urge Switch from Noritren over Carcinogen Risks, but Continues Shipments
  June 8, 2023

• LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
  June 8, 2023

• LDP League Submits Proposal to Ensure Stable Generic Supplies
  June 8, 2023

• Draft Honebuto Paper Unveiled, Cabinet OK Expected in Mid-June
  June 8, 2023

• Expert Panel Broadly OKs Draft Report on Pharma Policies, Further Deliberations by Other Forums
  June 7, 2023

• Draft Honebuto Paper Calls for Further Drug Pricing Measures to Reward Innovation
  June 7, 2023

• Japan Unveils Healthcare DX Timeline, Set to Drive Secondary Data Usage by Drug Makers
  June 6, 2023

• Japan Likely to Approve Its 1st Cold Meds Containing Loxoprofen
  June 6, 2023

• LDP Project Team Submits Proposal to Prime Minister
  June 5, 2023

• Expert Panel to Propose Setting Up Requirements for Generic Entry to Ensure Stable Supplies; Draft Report Due Out June 6
  June 5, 2023

• Expert Panel Wants to See Action on Excessive Yakkasa, No Direction on Buffer Zone: Draft Report
  June 5, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 80
• 81
• 82
• 83
• 84
• 85
• 86
• 87
• 88
• …
• Next ›
• 最終 »